New Findings on Optimizing Care for Patients, Improving Access, and Developing Novel Treatments to be Presented at Largest Global Clinical Cancer Research Meeting

For immediate release
May 9, 2023


Rachel Cagan Facci

ALEXANDRIA, Va. – Oncology professionals from around the world will convene in Chicago to discuss the latest clinical cancer research impacting patient care at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Optimizing care for patients, improving access to cancer care, and developing novel treatments are among the topics that will be highlighted in the meeting’s official Press Program.  

The 2023 ASCO Annual Meeting will take place June 2-6 in Chicago and online. The theme of this year’s conference is Partnering With Patients: The Cornerstone of Cancer Care and Research. 

More than 5,500 abstracts will be presented or published at the ASCO Annual Meeting. ASCO will publish the regular abstracts on Thursday, May 25, at 5:00 PM (ET) on Late-Breaking Abstracts (LBAs), including Plenary abstracts, will be released at 7:00 AM (CT)/8:00 AM (ET) on their day of scientific presentation at the meeting. The complete embargo schedule is available online


In advance of the release of regular abstracts on May 25, an embargoed, virtual press briefing for media will be held on May 22 and will highlight six abstracts. The embargo will lift on May 25 at 5:00 PM (ET) for the following studies:

  • A randomized phase III trial evaluating the impact of a telephone-based weight loss intervention in patients with breast cancer. (Abstract 12001
  • A study examining the effect of Medicaid expansion on racial disparities in mortality among patients with gastrointestinal cancers. (Abstract 6546)
  • A study examining sustainable childhood leukemia care in the US-Mexico border using health systems strengthening models. (Abstract 1502)
  • A randomized trial assessing the safety of minimally invasive distal pancreatectomy in patients with resectable pancreatic cancer. (Abstract 4163
  • A phase III study comparing the efficacy and safety of luspatercept and epoetin alfa in patients with lower‑risk myelodysplastic syndromes. (Abstract 7003) 
  • A phase III study comparing pembrolizumab and chemotherapy versus placebo and chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer. (Abstract 5500) 


In advance of the release of Late-Breaking Abstracts (LBAs) on June 2 and 3, an embargoed, virtual press briefing for media will be held on May 31 and will highlight three abstracts:

  • A randomized phase III trial comparing radical hysterectomy to simple hysterectomy in women with low-risk early-stage cervical cancer. (Abstract LBA5511) 
    Embargo lifts Friday, June 2 at 7:00 AM (CT)/8:00 AM (ET) 
  • A phase III study examining ribociclib and endocrine therapy as adjuvant treatment in pre- and postmenopausal patients with HR+/HER2− early breast cancer. (Abstract LBA500)
    Embargo lifts Friday, June 2 at 7:00 AM (CT)/8:00 AM (ET) 
  • A randomized phase III trial looking at durvalumab with paclitaxel/carboplatin and bevacizumab followed by maintenance durvalumab, bevacizumab, and olaparib in patients with newly diagnosed advanced ovarian cancer. (Abstract LBA5506
    Embargo lifts Saturday, June 3 at 7:00 AM (CT)/8:00 AM (ET) 


During the Annual Meeting, press briefings will be held on Saturday, June 3 from 1:00-2:00 PM (CT), and Sunday, June 4 from 8:00-9:00 AM (CT). LBAs that will be featured in these on-site press briefings include:

  • A randomized phase III trial comparing neoadjuvant chemoradiation and neoadjuvant FOLFOX chemotherapy followed by total mesorectal excision for locally advanced rectal cancer. (Abstract LBA2) 
    Embargo lifts Sunday, June 4 at 7:00 AM (CT)/8:00 AM (ET)  
  • A phase III trial assessing survival after treatment with adjuvant osimertinib in patients with resected EGFR‑mutated non-small cell lung cancer. (Abstract LBA3) 
    Embargo lifts Sunday, June 4 at 7:00 AM (CT)/8:00 AM (ET) 
  • A randomized phase III study comparing vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma. (Abstract LBA1) 
    Embargo lifts Sunday, June 4 at 7:00 AM (CT)/8:00 AM (ET) 
  • A phase III study comparing nivolumab and brentuximab vedotin in patients with advanced stage classic Hodgkin lymphoma. (Abstract LBA4)
    Embargo lifts Sunday, June 4 at 7:00 AM (CT)/8:00 AM (ET)  
  • A phase III study evaluating mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression (LBA5507)
    Embargo lifts Sunday, June 4 at 7:00 AM (CT)/8:00 AM (ET)  
  • A study examining the efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors. (Abstract LBA3000)
    Embargo lifts Monday, June 5 at 7:00 AM (CT)/8:00 AM (ET)  
  • The first report from a phase 3 trial evaluating ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma. (LBA106)
    Embargo lifts Monday, June 5 at 7:00 AM (CT)/8:00 AM (ET)  
  • A prospective trial analyzing observation compared to radiotherapy in patients with primary mediastinal B-cell lymphoma. (Abstract LBA7505) 
    Embargo lifts Tuesday, June 6 at 7:00 AM (CT)/8:00 AM (ET) 

All press briefings will be recorded and made available to credentialed reporters in ASCO’s Media Headquarters. A complete, detailed press briefing schedule noting which abstracts will be highlighted each day and when these abstracts will be publicly released is also available online.


Media registration: To participate in the Annual Meeting press briefings and/or register to attend the Meeting in person in Chicago, please visit ASCO’s Media Headquarters at Step-by-step instructions are available online

Media Headquarters submission must be completed no later than Wednesday, May 17, to participate in the pre-meeting press briefing on May 22. Pre-registration is required for on-site attendance and must be completed by this date. 

Annual Meeting Media Resource Center: Visit for press releases, the press briefing schedule, embargo policies, high-resolution photos, and the Virtual Press Room (an online repository of corporate and institutional press materials from third-party organizations). 

Cancer.Net: Visit ASCO’s lay-friendly website featuring the latest, comprehensive oncologist-approved information about cancer diagnosis, statistics, treatment, survivorship, and more. This trustworthy resource can help ensure your reporting is accurate, informative, and accessible to a wide audience. 




About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.